LSTA: Multiplikator Forward P/S Lisata

Lambang korporat lan logo Lisata Therapeutics, Inc. (LSTA)

Lisata Therapeutics (LSTA) is developing scalable solutions to combat solid tumors, aiming for a monopoly in the drug market. This chart on the GURU.Markets platform illustrates the business's forward P/S, which currently stands at 131.50. The model relies on CendR technology to enhance chemotherapy for pancreatic cancer. David Mazzo's team, backed by strong scientific expertise, is successfully advancing Phase II clinical trials.

LSTA Lisata Therapeutics Inc.: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 02.03.2025 - 15.11.2026

Ringkesan rincian data analitis Lisata Therapeutics Inc. (LSTA)

- rega saham lan target rega konsensus:
Kutipan saham Lisata Therapeutics, Inc.|LSTA - Rega prakiraan analis
- informasi kapitalisasi pasar:
Kapitalisasi pasar Lisata Therapeutics|LSTA - Nilai Wutuh Bisnis
- statistik nilai buku emiten:
Aset Bersih saben Siji Saham Lisata Therapeutics|LSTA - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku lisata.com|LSTA - Nilai Agregat Aset
- indikator beban utang lan likuiditas:
Utang marang Ekuitas Lisata Therapeutics|LSTA - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas lisata.com|LSTA - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Lisata Therapeutics, Inc.|LSTA - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Lisata Therapeutics|Likuiditas cepet lisata.com
- data bathi bisnis lan rasio investasi:
LSTA - Asil keuangan resik|Proyeksi bathi mangsa ngarep Lisata Therapeutics|LSTA - Pangali P/E|Prakiraan rega marang bathi Lisata Therapeutics, Inc.|LSTA - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Lisata Therapeutics|LSTA - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Lisata Therapeutics|LSTA - Bathi saben saham sajroning taun lumaku|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan lisata.com|LSTA - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Lisata Therapeutics
- rincian pendapatan lan dodolan:
LSTA - Pendapatan dodolan perusahaan|Prakiraan volume dodolan Lisata Therapeutics, Inc.|LSTA - Rega marang dodolan|Rasio rega marang prakiraan pendapatan Lisata Therapeutics Inc.
Analisis komprehensif perusahaan:LSTA (lisata.com)
Produk asli Lisata Therapeutics, Inc.

Forward P/S measures an asset's market value relative to projected sales, making it possible to distinguish an undervalued asset from a stagnating business. The current value of 131.50 for the expected price-to-sales ratio reflects the scaling potential of the Lisata Therapeutics (LSTA) oncology drug delivery platform, helping investors assess the efficiency of commercial expansion and the risks of capital freeze while searching for a market bottom.

Karo sapa Lisata Therapeutics saingan

Geron - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake NBTX (Nanobiotix Corp)|Bicycle Pharma - Multiplikator Forward P/S|Rega mangsa ngarep marang pendapatan CTMX|perspectivetherapeutics.com (CATX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Genelux Corp (GNLX)|Rasio rega marang prakiraan pendapatan Molecular Partners|ONCY: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Moleculin Biotech Inc (MBRX)|Multiplikator forward rega marang pendapatan Galera Therapeutics Inc. GRTX|Rasio rega marang prakiraan pendapatan Molecular Templates Inc MTEM